NCT07254988Terminated
Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Reason given: Terminated since further recruitment proved difficult
Brief summary (registry, in English)
Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.
- Status (registry)
- Terminated
- Study type
- Interventional
- Enrollment
- 3 (actual)
- First submitted
- 19 Nov 2025
- Start date
- 24 Mar 2023
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- University of Copenhagen
- NCT number
- NCT07254988
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of anti-resorptive medication
Other illness
- Confounding illnesses
- Allergy towards the components given on the test days
Lab values
- Hgb<6.5 mmol/L
Other
- Pregnancy
Who the study is looking for
- Diagnosis with Cerebral palsy (CP), Duchenne muscular dystrophy (DMD) or Spinal muscular atrophy (SMA) resulting in the need of a wheelchair
Age in the registry: 10 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet | Copenhagen | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.